PHVS – pharvaris n.v. - ordinary shares (US:NASDAQ)
Stock Stats
News
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology [Yahoo! Finance]
KalVista Pharmaceuticals: Has Potential But With Caveats [Seeking Alpha]
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
Pharvaris (PHVS) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $52.00 price target on the stock.
Pharvaris (PHVS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Glassman Robert
Form 3 Pharvaris N.V. For: Mar 17 Filed by: Schikan Johannes Gerardus Christiaan Petrus
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Abele Stefan Andreas
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Lesage Anne
Form 3 Pharvaris N.V. For: Mar 18 Filed by: Nassif David W.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.